Why Eupraxia Pharmaceuticals EPRX guidance matters more than actual results Q4 2025 Below Expectations What Pinnacle PNW segment performance reveals Q4 2025 Better Than Expected State Street Materials Select Sector SPDR ETF XLB Investment Viability Analysis for 2026 and Beyond Walmart Inc WMT Outlines Wellness Beverage Growth Strategy at 2026 Industry Beverage Forum CTKB Q1 2026 Earnings EPS Misses Estimates as Operating Losses Widen ProQR Therapeutics Q1 2026 Earnings Narrower Net Loss No Revenue as Pipeline Progress Drives Stock Gains Vertical Aerospace Q4 2025 Earnings EPS Miss Reflects Ongoing RD Investment PreRevenue Status Maintained OTLY Q1 2026 Earnings Losses Narrow Sharply as Cost Improvements Exceed Expectations CRVO Q1 2026 Earnings EPS Miss Reflects Continued Clinical Investment KULR Q3 2025 Earnings A Significant EPS Miss Raises Questions Amid Operational Transition